Shakespeare Martineau advises Levrett on flotation
ADVISERS at Birmingham-based law firm Shakespeare Martineau have successfully aided Levrett to float on the London Stock Exchange.
London-based Levrett is a special purpose acquisition company formed to acquire realisable and/or developed commercial technologies and focused on the pharmaceutical and biotechnology sectors.
Areas that will be of focus and will benefit from technological advances include the diagnosis and treatment of serious illnesses such as cancer, cardiovascular and respiratory disease, obesity and diabetes.
Shakespeare Martineau advised the firm through an initial public offering (IPO).
Keith Spedding, corporate partner at Shakespeare Martineau who led the team advising Levrett, said: “This is a confident move by Levrett and signifies its future growth ambitions by opening up opportunities to raise additional capital. The success of the move is testament to the growing interest in the biotechnology market.”
“The appetite for IPOs is beginning to pick up pace as we see business confidence improving and further stability in the market during the coming months will, in turn, increase demand in the public markets.”
Pascal Hughes, CEO of Levrett, said: “We are very pleased to have successfully concluded the placing and admission of Levrett with the help of Keith’s team.
“There are a number of very exciting opportunities in the pharmaceutical and biotechnology sectors which we look forward to exploring further.”
